Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

168 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study hypothesizes that Drug -eluting stents are more effective in preventing restenosis than Bare-metal stents after Vertebral Artery Ostium stenting

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug Eluting Stents Versus Bare Metal Stents for Treatment of Symptomatic Extracranial Vertebral Artery Stenosis

NCT03201432

Ischemic Stroke Vertebral Artery Stenosis

COMPLETED PHASE2/PHASE3

Drug Coated Balloon Versus Stenting in Patients With Symptomatic Vertebral Artery Stenosis：an Observational Clinical Study

NCT03311360

Vertebral Artery Origin Stenosis

COMPLETED

AcoArt VI / Vertebral Artery Ostium Stenosis in China

NCT03910166

Ischemic Stroke Transient Ischemic Attack

COMPLETED NA

Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis

NCT00811772

Coronary Atherosclerosis Angina Pectoris Myocardial Infarction

COMPLETED NA

Critical Treatment of Coronary Artery Disease

NCT03195621

Coronary Artery Disease Coronary Artery Disease Progression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The vertebral artery ostium stenosis was one of the higher risk of the ischemia stroke in China. In the mean time ,more and more people accept revascularization. There are no prospective studies for comparison of prevention of restenosis after Drug -eluting stents and Bare-metal stents until now.

The main aim of this study is to observe the following details:

1. Late loss in lumen diameter in follow-up ≥50%
2. Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs
3. Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs

Secondary endpoint:

brain, gastrointestinal and urinary system bleeding in 12 months follow-up

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BMS group, DES group

All the participants in this group will be performed with bare-metal stents or drug -eluting stents

DES group

Intervention Type PROCEDURE

all the participants in this group will be performed with drug -eluting stents

BMS group

Intervention Type PROCEDURE

all the participants in this group will be performed with bare-metal stents

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DES group

all the participants in this group will be performed with drug -eluting stents

Intervention Type PROCEDURE

BMS group

all the participants in this group will be performed with bare-metal stents

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Drug -eluting stents group Bare-metal stents group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- symptomatic posterior circulation ischemia including monor stroke (mRS ≤2) or TIA result from the stenosis in the vertebral artery ostium.

70% to 99% stenosis of vertebral artery ostium.

Exclusion Criteria

* etiology of stenotic lesions not atherosclerosis patients had undergone previos interventions on the vertebral artery ostium ipsilateral severe stenotic lesions in subclavian artery involved as well as vertebral artery ostium

Minimum Eligible Age

35 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No